Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVER3: Home-treatment Algorithm for Early COVID-19
NCT05249790Phase 3Withdrawn
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Feb 2022
- Primary completion
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands
01
Overview
A Phase 3 trial of dexamethasone, low molecular weight heparin calcium in coronavirus disease 2019 (COVID-19), sponsored by Mario Negri Institute for Pharmacological Research. Planned start Feb 2022; status: withdrawn.
02
Drugs
dexamethasonelow molecular weight heparin calcium
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05249790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05249790.